Since it was founded in 2000, QB3 has worked to spin out research from UC Berkeley, UC Santa Cruz and UCSF into standalone companies or to unite researchers with larger companies.
Drugs companies Bayer HealthCare and Roche have both signed three-year agreements with the California Institute for Quantitative Biosciences (QB3) to evaluate companies in life sciences with the aim of working together to advance early-stage technologies and therapeutics. Venture capital firm Mission Bay Capital will provide seed funding to the selected companies. Scientists based at Bayer’s…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
